Difference between revisions of "SL327"
Jump to navigation
Jump to search
(added injection parameters) |
(Update perm redirect.) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
SL327 is a MAP Kinase Kinase 1/2 (MEK1/2) inhibitor. | SL327 is a MAP Kinase Kinase 1/2 (MEK1/2) inhibitor. | ||
| − | [ | + | [https://www.sigmaaldrich.com/US/en/product/sigma/s4069 Sigma-Aldrich S4069-5MG] $101 |
Synonym: α-[Amino-(4-aminophenylthio)methylene)-2-(trifluoromethyl)phenylacetonitrile | Synonym: α-[Amino-(4-aminophenylthio)methylene)-2-(trifluoromethyl)phenylacetonitrile | ||
Latest revision as of 11:14, 7 December 2021
SL327 is a MAP Kinase Kinase 1/2 (MEK1/2) inhibitor.
Synonym: α-[Amino-(4-aminophenylthio)methylene)-2-(trifluoromethyl)phenylacetonitrile
CAS Number: 305350-87-2
Empirical Formula (Hill Notation): C16H12F3N3S
Molecular Weight: 335.35
MDL number: MFCD06411432
Central Administration
From Kwon and Houpt, 2011:
Dissolve SL327 in 50% DMSO, 50% 0.15M NaCl at 2 ug/ul concentration.. Administer using Hamilton syringe pump over 1 minute: 1 ug/0.5 ul / hemisphere into the CeA immeadiately after 10min access to 0.125% saccharin and 15 min before LiCl injection (12 ml/kg, 0.15 M, i.p.) Inject 0.5 ul over 1 minute; leave injector in place for 1 min after injection to prevent backflow along the injection tract.